Bermudez-Gonzalez Jorge Luis, Sanchez-Quintero Denya, Proaño-Bernal Leonardo, Santana-Apreza Rafael, Jimenez-Chavarria Marco Antonio, Luna-Alvarez-Amezquita Jose Antonio, Straface Juan Ignacio, Perez-Partida Arantza Marie, Berarducci Joaquin, Armenta-Moreno Javier Ivan, Garza-Cruz Karla Joana, Espinola-Zavaleta Nilda, Alexanderson-Rosas Erick
National Institute of Cardiology Ignacio Chavez, Juan Badiano 1, Belisario Dominguez Secc 16, Tlalpan, Mexico City 14080, Mexico.
Faculty of Medicine, National Autonomous University of Mexico, Escolar 411 A, Copilco Universidad, Coyoacan, Mexico City 04360, Mexico.
Antioxidants (Basel). 2022 Mar 25;11(4):627. doi: 10.3390/antiox11040627.
Ischemia-reperfusion injury is a common problem in the age of interventional cardiology; it is primarily mediated by oxidative stress and reactive agents. Melatonin has antioxidative properties that make its use promising for treating ischemia-reperfusion injury. Multiple experimental studies in murine and porcine models have been performed with good results. Clinical trials have also been conducted but given their heterogeneity, no conclusive results can be made. Melatonin pharmacokinetic properties are not ideal; therefore, many analogs have been proposed with improved characteristics, and some studies have evaluated their efficacy in animal models, but clinical trials are needed to recommend their use. In this review, we expose the results of the most impactful studies regarding melatonin use in ischemia-reperfusion injury.
缺血再灌注损伤是介入心脏病学时代的一个常见问题；它主要由氧化应激和活性物质介导。褪黑素具有抗氧化特性，这使其在治疗缺血再灌注损伤方面具有应用前景。已经在小鼠和猪模型上进行了多项实验研究，结果良好。也开展了临床试验，但鉴于其异质性，无法得出确凿结论。褪黑素的药代动力学特性并不理想；因此，人们提出了许多具有改进特性的类似物，一些研究评估了它们在动物模型中的疗效，但需要进行临床试验以推荐其使用。在本综述中，我们阐述了关于褪黑素用于缺血再灌注损伤的最具影响力的研究结果。
